Antibodies: Do you want to find out how to take your alternative scaffold through the clinic and to the market?
Dr Andrew Nixon, Senior Director at Dyax Corporation did this just this with ecallantide (DX-88), a scaffold which targets human plasma kallikrein for treatment of hereditary angioedema (HAE)
Follow the link below for the presentation slides delivered at the 2011 European Antibody Congress, and find out the details!
Do you want to find out more?
Bispecific #Antibody success story